Traverse: A Phase 2, Open-Label, Randomized Study of Acalabrutinib in Combination with Venetoclax and Rituximab in Patients with Treatment-Naive Mantle Cell Lymphoma

被引：2
|
作者：
Hawkes, Eliza A. [1 ]
Fletcher, Rachel [2 ]
Wood, Andrew [2 ]
Meyer, Stefanie [3 ]
Rule, Simon [4 ]
Zhang, Jingyang [5 ]
Wang, Michael L. [6 ]
机构：
[1] Austin Hlth, Olivia Newton John Canc Res & Wellness Ctr, Heidelberg, Vic, Australia
[2] AstraZeneca, Cambridge, England
[3] AstraZeneca, Waltham, MA USA
[4] AstraZeneca, Mississauga, ON, Canada
[5] AstraZeneca, San Francisco, CA USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-174718
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Phase 2, open-label study of venetoclax in combination with carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
    Bueno, Orlando
    Xu, Tu
    Cordero, Jaclyn
    Morris, Lura
    Ross, Jeremy
    Freise, Kevin
    Munasinghe, Wijith
    Leverson, Joel
    Mudd, Sarah
    Verdugo, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [32] MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naive Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses
    Ruan, Jia
    Bond, David A.
    Shah, Bijal
    Allan, John N.
    Rutherford, Sarah C.
    Gribbin, Caitlin
    Chen, Zhengming
    Hobbie, Brittany
    Harbhajan, Melinda
    Sahni, Tejasvi
    Tam, Wayne
    Bhinder, Bhavneet
    Sigouros, Michael
    Inghirami, Giorgio
    Chen-Kiang, Selina
    Elemento, Olivier
    Maddocks, Kami J.
    Leonard, John P.
    Martin, Peter
    BLOOD, 2024, 144 : 746 - 747
  • [33] Pharmacokinetics, Safety, and Efficacy of Acalabrutinib in Chinese Patients with Relapsed/Refractory Mantle Cell Lymphoma and Other B-Cell Malignancies: An Open-Label, Multicenter Phase 1/2 Trial
    Zhu, Jun
    Song, Yuqin
    Li, Jianyong
    Zhou, Keshu
    Ke, Xiaoyan
    Cai, Zhen
    Zhang, Huilai
    Yao, Tingting
    Xia, Zhen
    Wang, Yiqiu
    Lai, Peiqiong
    Liu, Xiaofeng
    BLOOD, 2022, 140 : 6496 - 6497
  • [34] A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naive myelofibrosis.
    Ali, Haris
    Kishtagari, Ashwin
    Maher, Keri Renee
    Mohan, Sanjay
    Mazumder, Amitabha
    Chamoun, Kamal
    Karasik, Igor
    Sbar, Eric
    Dugon, Laura
    Tamir, Sharon
    Wang, Xulong
    Prchal, Josef T.
    Tantravahi, Srinivas Kiran
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] Open-Label Bendamustine Combined with Rituximab for Treatment of Relapsed/Refractory Mantle-Cell Lymphoma: Efficacy and Safety Findings
    Czuczman, Myron S.
    Lamonica, Dominick
    Gaylor, Shari K.
    Bush, Leonard
    Nadolny, Penny
    Colborn, Dave
    BLOOD, 2012, 120 (21)
  • [36] The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III trial of the European mantle cell lymphoma network
    Fischer, Luca
    Jiang, Linmiao
    Duerig, Jan
    Schmidt, Christian
    Stilgenbauer, Stephan
    Bouabdallah, Krimo
    Solal-Celigny, Philippe
    Scholz, Christian W.
    Feugier, Pierre
    de Wit, Maike
    Trappe, Ralf Ulrich
    Hallek, Michael
    Graeven, Ullrich
    Haenel, Mathias
    Hoffmann, Martin
    Delwail, Vincent
    Macro, Margaret
    Greiner, Jochen
    Giagounidis, Aristoteles A. N.
    Dargel, Beate
    Durot, Eric
    Foussard, Charles
    Silkenstedt, Elisabeth
    Weigert, Oliver
    Pott, Christiane
    Klapper, Wolfram
    Hiddemann, Wolfgang
    Unterhalt, Michael
    Hoster, Eva
    Ribrag, Vincent
    Dreyling, Martin
    LEUKEMIA, 2024, 38 (06) : 1307 - 1314
  • [37] An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma
    Andorsky, David J.
    Kolibaba, Kathryn S.
    Assouline, Sarit
    Forero-Torres, Andres
    Jones, Vicky
    Klein, Leonard M.
    Patel-Donnelly, Dipti
    Smith, Mitchell
    Ye, Wei
    Shi, Wen
    Yasenchak, Christopher A.
    Sharman, Jeff P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (02) : 215 - 222
  • [38] A Phase II Study of the Combination of Lenalidomide and Rituximab in Patients with Treatment-NaiVe and Relapsed Chronic Lymphocytic Leukemia
    Strati, Paolo
    Thompson, Philip A.
    Keating, Michael
    Hinojosa, Christina
    Rodriguez, Diana
    Wang, Xuemei
    Daver, Naval G.
    Jain, Nitin
    Burger, Jan A.
    Estrov, Zeev
    Wierda, William G.
    Kantarjian, Hagop M.
    Obrien, Susan
    Ferrajoli, Alessandra
    BLOOD, 2016, 128 (22)
  • [39] A phase III open label randomized study to compare the efficacy of lenalidomide-rituximab vs bendamustine-rituximab in treatment naive follicular lymphoma.
    Paikaray, Susanta Kumar
    Gogia, Ajay
    Kumar, Lalit
    Sharma, Atul
    Biswas, Ahitagni
    Sharma, Mehar C.
    Thulker, Sanjay
    Kumar, Rakesh
    Vishnubhatla, Sreenivas
    Mallick, Saumyaranjan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [40] Maraviroc Once-Daily Nucleoside Analog-Sparing Regimen in Treatment-Naive Patients: Randomized, Open-Label Pilot Study
    Mills, Anthony
    Mildvan, Donna
    Podzamczer, Daniel
    Faetkenheuer, Gerd
    Leal, Manuel
    Than, Soe
    Valluri, Srinivas R.
    Craig, Charles
    McFadyen, Lynn
    Vourvahis, Manoli
    Heera, Jayvant
    Valdez, Hernan
    Rinehart, Alex R.
    Portsmouth, Simon
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2013, 62 (02) : 164 - 170
12345